Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.70 |
| ▸ | THRB | P10828 | 7/20 | 0.70 |
| ▸ | BLM | P54132 | 6/20 | 0.70 |
| ▸ | TOP2A | P11388 | 5/20 | 0.70 |
| ▸ | RECQL | P46063 | 5/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | BRCA1 | P38398 | 4/20 | 0.70 |
| ▸ | HTT | P42858 | 4/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.70 |
| ▸ | FYN | P06241 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2623847 | 1.00 | MEN1 (0.70) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL2623850 | 1.00 | MEN1 (0.70) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL2632461 | 0.94 | MEN1 (0.71) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL17775538 | 0.94 | MEN1 (0.71) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL22430759 | 0.94 | MEN1 (0.73) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL16144207 | 0.94 | MEN1 (0.68) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL20081214 | 0.94 | MEN1 (0.68) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL2623852 | 0.94 | MEN1 (0.72) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL24341972 | 0.92 | MEN1 (0.65) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL17775622 | 0.91 | MEN1 (0.64) | MEN1KMT2ATHRBBLMTOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160143937-A1 | METHODS OF USING CLEAVABLE DRUG CONJUGATES AND COMPOSITIONS THEREOF | Nguyen, Mark Quang (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160129027-A1 | CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE | Nguyen, Mark Quang (US) | 2016-05-12 | — | — | US | disclosed |
| US-9295731-B2 | Cleavable drug conjugates, compositions thereof and methods of use | Nguyen, Mark Quang (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140294851-A1 | CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE | Nguyen, Mark Quang (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129027-A1 | CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE | PAICS, FOLH1, DHFR | MEN1 681/4885KMT2A 2629/4885THRB 3951/4885 |
| US-20140294851-A1 | CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE | PAICS, FOLH1, DHFR | MEN1 681/4885KMT2A 2629/4885THRB 3951/4885 |
| US-20160143937-A1 | METHODS OF USING CLEAVABLE DRUG CONJUGATES AND COMPOSITIONS THEREOF | SI, PAICS, FURIN | MEN1 845/4885KMT2A 2706/4885THRB 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.